Governance

Board of Directors

At PolarityTE, our board members are selected based on rigorous review. If you are interested in learning more about our process, download the respective documents below.

Peter Cohen

Peter Cohen

Chairman of the Board

Mr. Cohen previously served on the Board of Directors at the NYSE, as well as previously serving as the CEO and Chairman of the Board of Cowen Inc., Shearson Lehman Cowen, and Republic New York Securities. Mr. Cohen is currently a Trustee of Mount Sinai Medical Center, a Member of the Board of Directors of Quadrant Biosciences, Inc., and Vice Chairman and Lead Director of the Board of Directors of Scientific Games Corporation. Additionally, Mr. Cohen has previously served on a number of other corporate and industry boards, including The Federal Reserve International Capital Markets Advisory Committee, American Express, The Depository Trust Company, Telecom Italia SpA, Olivetti SpA, and Kroll Inc. He obtained a Masters of Business Administration from Columbia University in 1969 and a Bachelor of Science from The Ohio State University in 1968.

Jon Mogford

Jon Mogford, PhD

Director

Dr. Jon Mogford, has served in various capacities for the Texas A&M University System. Since May 2013, Dr. Mogford has served as the Vice Chancellor for Research, from August 2012 until April 2013 he served as the Chief Research Officer and from November 2011 until August 2012 he served as Associate Vice Chancellor for Strategic Initiatives at Texas A&M. Prior to joining the Texas A&M in 2011, from February 2010 until October 2011, Dr. Mogford served as Deputy Director of the Defense Sciences Office (DSO) of the Defense Advanced Research Projects Agency (DARPA) in the U.S. Department of Defense. From July 2005 until January 2009, Dr. Mogford served as Program Manager of DSO of DARPA. In addition, since November 2016, Dr. Mogford has served as a member of the board of directors of Medovex Corp. Dr. Mogford is the recipient of the Secretary of Defense Medal for Outstanding Public Service. Dr. Mogford received his bachelor’s degree in Zoology from Texas A&M University and doctorate in Medical Physiology from the Texas A&M University Health Science Center. His research in vascular physiology continued at the University of Chicago as a Postdoctoral fellow from 1997 until 1998. Dr. Mogford transitioned his research focus to the field of wound healing at Northwestern University, both as a Research Associate and also as a Research Assistant Professor from 1998 until 2003. He then served as a Life Sciences Consultant to DARPA on the Revolutionizing Prosthetics program from December 2003 until June 2005. Dr. Mogford experience and research in regenerative medicine is particularly helpful as a board member.

Minnie Baylor-Henry

Minnie Baylor-Henry, JD

Director

Minnie Baylor-Henry is a regulatory affairs leader who provides regulatory strategic support services to life sciences companies through her consulting firm, B-Henry & Associates. Before starting her consulting company, Ms. Baylor-Henry was employed by Johnson & Johnson and members of the J&J health care group in a number of positions, including: Worldwide Vice President Regulatory Affairs - Medical Devises, Vice President - Medical & Regulatory Affairs – Specialty Pharmaceuticals, and Vice President-Regulatory Affairs – Over-the-Counter Products, and Senior Director, Regulatory Affairs. Ms. Baylor-Henry also served as the National Director Regulatory Affairs Life Sciences for Deloitte. In addition, Ms. Baylor-Henry served for nearly in decade in several positions with the U.S. Food & Drug Administration, including Director/Branch Chief – Division of Drug Marketing, Advertising and Communications, National Health Fraud Coordinator – Office of Regulatory Affairs/ Federal/ State Relations, and Regulatory Review Officer. Ms. Baylor-Henry also serves as a Director of scPharmaceuticals, Inc., a publicly-held company engaged in the business of developing technologies that enable the subcutaneous administration of therapies that have previously been limited to intravenous delivery. Ms. Baylor-Henry received her pharmacy degree from Howard University’s College of Pharmacy and a law degree from Catholic University’s Columbus School of Law.

Willie Bogan

Willie Bogan, JD

Director

Willie Bogan served as Associate General Counsel and Corporate Secretary of McKesson Corporation, a San Francisco-based healthcare services and information technology company, from July 2009 until his retirement in November 2015. He joined McKesson in November 2006 as Associate General Counsel and Assistant Secretary. Before joining McKesson, Mr. Bogan held senior advisory positions at four other public companies in the San Francisco Bay Area – Bank of America, Safeway, Charles Schwab and Catellus Development Corporation. Prior to becoming in-house counsel, he was a partner at Steinberg, Miller, Bogan & Goldstein in Manhattan Beach, California.During his tenure as a business and securities attorney, Mr. Bogan was involved in a variety of substantial commercial transactions and was an advisor to directors and executive management in the boardroom. Through this, Mr. Bogan acquired significant business and financial experience, including in relation to lending, borrowing, hedging, capital deployment, financial results, mergers and acquisitions, risks and risk management. Regarding healthcare, he acquired significant insight into supply chain systems and activities, and into the nature, opportunities and challenges of healthcare technology businesses. Mr. Bogan also has extensive corporate governance experience. Mr. Bogan graduated Phi Beta Kappa and Summa Cum Laude from Dartmouth College, where he majored in Spanish. He earned an MA degree in Politics and Economics from Oxford University, where he studied as a Rhodes Scholar, and a JD degree from Stanford Law School. While at Dartmouth, Mr. Bogan was an All-Ivy, All New-England, All-East and Academic-All American defensive back on the undefeated and nationally ranked 1970 football team and was drafted by the then Baltimore Colts. In addition, he was named a National Football Foundation and Hall of Fame scholar-athlete. In 1989, he was inducted into the Academic All-America Hall of Fame, an honor that recognizes former Academic All-Americans for career achievements

Jeff Dyer

Jeff Dyer, MBA, PhD

Director

Jeff Dyer is the Horace Beesley professor of strategy at Brigham Young University (BYU), as well as a professor of strategy at the Wharton School, University of Pennsylvania. Before becoming a professor, Mr. Dyer spent five years as a consultant and manager at Bain & Company. His Harvard Press books on innovation, The Innovator's DNA (with Clayton Christensen) and The Innovator's Method are business bestsellers, and his research has been featured in publications such as Forbes, Economist, Fortune, BusinessWeek and the Wall Street Journal. Mr. Dyer is the only strategy scholar in the world to have published at least 6 times in both Harvard Business Review and Strategic Management Journal (the top academic journal in strategy). He was recently ranked #1 on a list of 'most influential management scholars' based upon academic citations and Google searches to his name (among management scholars who received their PhD's after 1990). Mr. Dyer is co-founder of Innovator's DNA LLC, a fast growing innovation consultancy, and has consulted with such companies as Adobe, AT&T, Cisco, Gilead Sciences, Johnson and Johnson, Life Technologies, Magellan Health, Microsoft, NuVasive, and United Technologies.

Ramses (Rainer) Erdtmann

Ramses (Rainer) Erdtmann

Director

Mr. Erdtmann is a Managing Partner at Point Sur Investors, a biotech investment fund focused on innovative therapies. Mr. Erdtmann previously worked at Pharmacyclics from 2008 through 2015 and remained with AbbVie as a consultant until 2016 post the acquisition of Pharmacyclics by AbbVie. During his time at Pharmacyclics, Mr. Erdtmann witnessed and helped grow Pharmacyclics from 47 employees and a market cap of $20 Million, to 634 employees and a market cap of $21 Billion. Mr. Erdtmann oversaw several departments and helped Pharmacyclics evolve into a fully integrated biotech company. He held a number of roles and, at various times, also had responsibility for Accounting, SEC Reporting, Audits, Corporate Communications and Investor Relations. He worked closely with the CEO and the Audit and Compensation Committee. Mr. Erdtmann actively participated in the final execution of key corporate milestones for Pharmacyclics, including the Collaboration Agreement with Johnson & Johnson in 2011 and the Merger Agreement with AbbVie in 2015.